PDF herunterladen
Thromb Haemost 2004; 91(04): 690-693
DOI: 10.1160/TH03-11-0680
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Treatment with anticoagulants in cerebral events (TRACE)

Ralph Woessner
1   Department of Neurology, Westpfalz-Klinikum GmbH, Kaiserslautern, Germany
,
Markus Grauer
2   Department of Neurology, Max-Planck Institute for Psychiatry, Munich, Germany
,
Oliver Bianchi
3   Department of Neurology, SHG-Kliniken, Merzig, Germany
,
Martin Mueller
4   Department of Neurology, University Hospital, University of the Saarland, Homburg, Germany
,
Stefan Moersdorf
5   Department of Hemostaseology, University Hospital, University of the Saarland, Germany
,
Peter Berlit
6   Department of Neurology, University of Essen, Germany
,
Michael Goertler
7   Department of Neurology, University of Magdeburg, Magdeburg, Germany
,
Karl-Heinz Grotemeyer
8   Department of Neurology, Klinikum Saarbrücken, Saarbrücken, Germany
,
Ulrich Sliwka
9   Department of Neurology, Klinikum Remscheid, Remscheid, Germany
,
Martin Stoll
1   Department of Neurology, Westpfalz-Klinikum GmbH, Kaiserslautern, Germany
,
Johannes Treib
1   Department of Neurology, Westpfalz-Klinikum GmbH, Kaiserslautern, Germany
› InstitutsangabenFinancial support: Our department has received funds from Aventis Pharma (formerly Rhone-Poulenc Rorer). All funds are administered and distributed through the departmental administration after a review process. None of the authors has received any funds personally.
Weitere Informationen

Publikationsverlauf

Received 08. November 2003

Accepted after revision 21. Januar 2004

Publikationsdatum:
06. Dezember 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Summary

90 patients with acute stroke and a concomitant cardiac embolism source or a symptomatic high-grade stenosis of an extraor intracranial vessel received in a mulitcenter, randomized, controlled study either Enoxaparin 1 mg/kg BW s.c. b.i.d. or i.v. heparin aPTT-adjusted daily for 8 +/−2 days as secondary prophylaxis. There were no significant differences between the two groups regarding cerebral and systemic embolic events, bleeding complications, length of hospital stay, number of diagnostic and therapeutic measures and outcome after three months. This suggests that Enoxaparin, which is easier to administer and monitor, is a safe drug in patients with acute cerebral events.

Keywords

Heparin - stroke - anticoagulants

* J Treib designed the study. All authors collected data, did the analyses and contributed to the writing of the report.


 

  • References

  • 1 Treib J, Grauer MT, Woessner R. et al. Treatment of stroke on an intensive stroke unit: a novel concept. Intensive Care Med 2000; 26: 1598-1611.
    CrossrefPubMedGoogle Scholar
  • 2 Estol CJ, Swanson RA. Intravenous heparin for acute stroke: What can we learn from the megatrials?. Neurology 2000; 54: 1542-6.
    PubMedGoogle Scholar
  • 3 Berge E, Abdelnoor M, Nakstad PH. et al. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000; 355: 1205-10.
    CrossrefPubMedGoogle Scholar
  • 4 The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998; 279: 1265-72.
    CrossrefPubMedGoogle Scholar
  • 5 Diener HC, Ringelstein EB, von Kummer R. et al. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators. Stroke 2001; 32: 22-9.
    CrossrefPubMedGoogle Scholar
  • 6 Bath PMW, Lindenstrom E, Boysen G. et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001; 358: 702-10.
    CrossrefPubMedGoogle Scholar
  • 7 Babaikain VL, Spencer M, Ackerstaff GA. et al. Basic identification criteria of Doppler microembolic signals. Stroke 1995; 26: 1123.
    CrossrefPubMedGoogle Scholar